Paranoid psychosis due to neurosarcoidosis.
We present two patients with known sarcoidosis who developed neurosarcoidosis manifested by paranoid psychosis and clinical diabetes insipidus with hypernatremia. Both had gadolinium enhanced magnetic resonance imaging which demonstrated leptomeningeal and hypothalamic enhancement. Both had elevated protein and a lymphocytosis in their cerebrospinal fluid, which improved after corticosteroid therapy. The patients improved clinically with this therapy as well. We suggest that new onset psychosis in a sarcoid patient, particularly with symptoms of hypothalamic/pituitary involvement, should be evaluated for neurosarcoidosis with an MRI and CSF examination. If the results are consistent with neurosarcoidosis, the patient should be treated promptly with corticosteroids.
Department of Internal Medicine, University of Cincinnati Medical Center, OH.
G M
GM
O'Brien
R P
RP
Baughman
J P
JP
Broderick
L
L
Arnold
E E
EE
Lower
D000328:Adult; D001581:Benzothiadiazines; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D003919:Diabetes Insipidus / Q000188:drug therapy / Q000209:etiology; D004232:Diuretics; D005260:Female; D006801:Humans; D006955:Hypernatremia / Q000188:drug therapy / Q000209:etiology; D008279:Magnetic Resonance Imaging; D008297:Male; D009422:Nervous System Diseases / Q000134:cerebrospinal fluid / Q000150:complications*; D010259:Paranoid Disorders / Q000134:cerebrospinal fluid / Q000209:etiology*; D012507:Sarcoidosis / Q000134:cerebrospinal fluid / Q000150:complications*; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D003894:Deamino Arginine Vasopressin